2013
DOI: 10.5812/hepatmon.14146
|View full text |Cite
|
Sign up to set email alerts
|

Consensus Interferon Plus Ribavirin for Hepatitis C Genotype 3 Patients Previously Treated With Pegylated Interferon Plus Ribavirin

Abstract: BackgroundNot enough data are available about the effectiveness of consensus interferon (CIFN) among HCV genotype 3 patients who failed to respond to pegylated interferon and ribavirin.ObjectivesWe aimed to assess the efficacy and safety of CIFN and ribavirin in non-responders and relapsers to pegylated interferon with ribavirin therapy.Patients and MethodsThis open-label investigator-initiated study included 44 patients who received CIFN 15 µg /day plus ribavirin 800-1200 mg daily. In patients with an early v… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1

Citation Types

0
2
0

Year Published

2015
2015
2019
2019

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(2 citation statements)
references
References 33 publications
0
2
0
Order By: Relevance
“…The Nonresponsiveness to IFNs is fairly common with varying rates in HCV infection. Response to IFN-α is observed in nearly 40-50% of patients with HCV infection, with improvement in rates by the addition of Ribavirin [9].…”
Section: Antiviral Effectsmentioning
confidence: 99%
“…The Nonresponsiveness to IFNs is fairly common with varying rates in HCV infection. Response to IFN-α is observed in nearly 40-50% of patients with HCV infection, with improvement in rates by the addition of Ribavirin [9].…”
Section: Antiviral Effectsmentioning
confidence: 99%
“…By organizing the total of 166 amino acids for all 13 IFN-α subtype keeping in view the more often signified amino acids from numerous IFN-α nonallelic subtypes at each position, a consensus sequence was determined. A commercially available U.S. Food and Drug Administration (FDA)-approved cIFN, Infergen (IFN alfacon-1 or cIFN) has 5-20-fold highest biopotency (higher antiproliferative and antiviral activity) [5,6]. cIFN is a second-generation type I IFN, and it is artificially formed by recombinant technology, which is created by the dint of multiple sequence alignment tools [7].…”
Section: Introductionmentioning
confidence: 99%